A uplc/ms-based metabolomics investigation of the protective effect of ginsenosides rg1 and rg2 in mice with alzheimer’s disease

Journal of Ginseng Research

Volumn 40, Issue 1, 2016, Pages 9-17

  Li, Naijing ^a   Liu, Ying ^b   Li, Wei ^b   Zhou, Ling ^b   Li, Qing ^b   Wang, Xueqing ^a   He, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Ginseng; Ginsenoside Rg1; Ginsenoside Rg2; Metabolomics

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GINSENOSIDE RG 1; GINSENOSIDE RG 2; HEXADECASPHINGANINE; HYPOXANTHINE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHYTOSPHINGOSINE; SPHINGANINE; SPHINGOLIPID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; ESCAPE BEHAVIOR; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; METABOLITE; METABOLOMICS; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PURINE METABOLISM; SPATIAL LEARNING; SPATIAL MEMORY; SPHINGOLIPID METABOLISM; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84954197574     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2015.04.006     Document Type: Article

References (45)

1. Inoue K, Tsutsui H, Akatsu H, Hashizume Y, Matsukawa N, Yamamoto T, Toyo’oka T. Metabolic profiling of Alzheimer’s disease brains. Sci Rep 2013;3: 2364-2372.
2. Wan W, Chen H, Li Y. The potential mechanisms of Abeta-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer’s disease. Int J Neurosci 2014;124:75-81.
3. Pratico D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharmacol Sci 2008;29:609-615.
4. Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta 2012;1822:286-292.
5. Tan X, Gu J, Zhao B, Wang S, Yuan J, Wang C, Chen J, Liu J, Feng L, Jia X. Ginseng improves cognitive deficit via the RAGE/NF-kB pathway in advanced glycation end product-induced rats. J Ginseng Res 2014;9:1-9.
6. Liu L, Huang J, Hu X, Li K, Sun C. Simultaneous determination of ginsenoside (G-Re, G-Rg1, G-Rg2, G-F1, G-Rh1) and protopanaxatriol in human plasma and urine by LCeMS/MS and its application in a pharmacokinetics study of G-Re in volunteers. J Chromatogr B 2011;879:2011-2017.
7. Li N, Liu B, Dluzen DE, Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007;111: 458-463.
8. Kim JH. Cardiovascular diseases and Panax ginseng: a review on molecular mechanisms and medical applications. J Ginseng Res 2012;36:16-26.
9. Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer’s amyloid peptide after oral administration of ginsenosides. Faseb J 2006;20:1269-1271.
10. Shi C, Zheng DD, Fang L, Wu F, Kwong WH, Xu J. Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim Biophys Acta 2012;1820:453-460.
11. Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013;37:8-29.
12. Nicholson JK, Lindon JC, Holmes E.’Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-1189.
13. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JTJ, Yuan P, Manji H, Holmes E, Bahn S. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatr 2009;14:269-279.
14. Want EJ, Nordströ m A, Morita H, Siuzdak G. From exogenous to endogenous. the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007;6:459-468.
15. Zheng X, Kang A, Dai C, Liang Y, Xie T, Xie L, Peng Y, Wang G, Hao H. Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-tandem mass spectrometry. Anal Chem 2012;84:10044-10051.
16. Wang X, Yang B, Sun H, Zhang A. Pattern recognition approaches and computational systems tools for ultra performance liquid chromatographymass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets. Anal Chem 2012;84:428-439.
17. Dai W, Wei C, Kong H, Jia Z, Han J, Zhang F, Wu Z, Gu Y, Chen S, Gu Q, et al. Effect of the traditional Chinese medicine tongxinluo on endothelial dysfunction rats studied by using urinary metabonomics based on liquid chromatography-mass spectrometry. J Pharmaceut Biomed 2011;56:86-92.
18. Li NJ, Liu WT, Li W, Li SQ, Chen XH, Bi KS, He P. Plasma metabolic profiling of Alzheimer’s disease by liquid chromatography/mass spectrometry. Clin Biochem 2010;43:992-997.
19. Liu Y, Li NJ, Zhou L, Li Q, Li W. Plasma metabolic profiling of mild cognitive impairment and Alzheimer’s disease using liquid chromatography/mass spectrometry. Cent Nerv Syst Agents Med Chem 2014;14:113-120.
20. Li X, Zhao X, Xu X, Mao X, Liu Z, Li H, Guo L, Bi K, Jia Y. Schisantherin A recovers Abeta-induced neurodegeneration with cognitive decline in mice. Physiol Behav 2014;132:10-60.
21. Liu Z, Zhao X, Liu B, Liu AJ, Li H, Mao X, Wu B, Bi KS, Jia Y, Jujuboside A. a neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral disorders of the dementia mouse model induced by Abeta 1-42. Eur J Pharmacol 2014;738:206-213.
22. Li Y, Ma Y, Zong L-X, Xing X-N, Guo R, Jiang T-Z, Sha S, Liu L, Cao Y-P. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Ab3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/ PSEN1dE9 mice. J Neuroimmunol 2012;249:16-26.
23. Ma Y, Li Y, Zong LX, Xing XN, Zhang WG, Cao YP. Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Abeta3-10 repeat fragment plasmid by reducing Abeta deposition and inflammatory response. Brain Res 2011;1400:112-124.
24. Yin P, Mohemaiti P, Chen J, Zhao X, Lu X, Yimiti A, Upur H, Xu G. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J Chromatogr B 2008;871:322-327.
25. Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharmaceut Biomed 2009;49:976-982.
26. Zhang H, Gao Y, Qiao PF, Zhao FL, Yan Y. Fenofibrate reduces amyloidogenic processing of APP in APP/PS1transgenic mice via PPAR- a/PI3-K pathway. Int J Dev Neurosci 2014;38:223-231.
27. Kim HY, Kim HV, Yoon JH, Kang BR, Cho SM, Lee S, Kim JY, Kim JW, Cho Y, Woo J, et al. Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer’s disease. Sci Rep 2014;4:7467-7473.
28. Bavaresco CS, Chiarani F, Matte C, Wajner M, Netto CA, de Souza Wyse AT. Effect of hypoxanthine on Naþ, Kþ-ATPase activity and some parameters of oxidative stress in rat striatum. Brain Res 2005;1041:198-204.
29. González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer’s disease by direct infusion mass spectrometry. J Pharmaceut Biomed 2015;102:425-435.
30. Xiang Z, Xu M, Liao M, Jiang Y, Jiang Q, Feng R, Zhang L, Ma G, Wang G, Chen Z, et al. Integrating genome-wide association study and brain expression data highlights cell adhesion molecules and purine metabolism in Alzheimer’s disease. Mol Neurobiol 2014;09:1-8.
31. Bavaresco CS, Chiarani F, Kolling J, Netto CA, Souza Wyse ATD. Biochemical effects of pretreatment with vitamins E and C in rats submitted to intrastriatal hypoxanthine administration. Neurochem Int 2008;52:1276-1283.
32. Wamser MN, Leite EF, Ferreira VV, Delwing-de Lima D, da Cruz JGP, Wyse ATS, Delwing-Dal Magro D. Effect of hypoxanthine, antioxidants and allopurinol on cholinesterase activities in rats. J Neural Transm 2013;120:1359-1367.
33. Melo JB, Agostinho P, Oliveira CR. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 2003;45:117-127.
34. Bavaresco CS, Chiarani F, Duringon E, Ferro MM, Cunha CD, Netto CA, Wyse AT. Intrastriatal injection of hypoxanthine reduces striatal serotonin content and impairs spatial memory performance in rats. Metab Brain Dis 2007;22:67-76.
35. Gonzalez-Dominguez R, García-Barrera T, Gomez-Ariza JL. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer’s disease. J Proteomics 2014;104:37-47.
36. Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology. Prog Lipid Res 2011;50:313-330.
37. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 2000;107:1027-1063.
38. Vestergaard MC, Morita M, Hamada T, Takagi M. Membrane fusion and vesicular transformation induced by Alzheimer’s amyloid beta. Biochim Biophys Acta 2013;1828:1314-1321.
39. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Paolo GD. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012;287:2678-2688.
40. Axelsen PH, Murphy RC. Quantitative analysis of phospholipids containing arachidonate and docosahexaenoate chains in microdissected regions of mouse brain. J Lipid Res 2010;51:660-671.
41. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta 2010;1801:878-886.
42. Alessenko AV. The potential role for sphingolipids in neuropathogenesis of Alzheimer’s disease. Biomed Khim 2013;59:25-50.
43. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2008;20:1010-1018.
44. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010;31:17-24.
45. Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? Neuromol Med 2010;12:331-340.